MedTrace Logo

Lefamulin for M. Genitalium Treatment Failures

NCT05111002 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2024-10-26

Study results available
· View outcomes & findings →

Summary

The purpose of this drug study is to find out whether the antibiotic lefamulin (trade name Xenleta) will cure Mycoplasma genitalium infections that have not been cured by prior antibiotics while finding out whether it is more effective if the antibiotic doxycycline is taken first.

Conditions

  • Mycoplasma Genitalium Infection

Interventions

DRUG

Lefamulin

600mg tablet orally twice daily

DRUG

Doxycycline

100mg tablet orally twice daily

Sponsors & Collaborators

Principal Investigators

  • Lisa E Manhart, PhD, MPH · University of Washington

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-22
Primary Completion
2023-11-30
Completion
2023-11-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05111002 on ClinicalTrials.gov